Drug Type Fusion protein |
Synonyms |
Target |
Mechanism CD73 inhibitors(5'-nucleotidase inhibitors), IL2RA inhibitors(Interleukin-2 receptor alpha chain inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | KR | 02 Nov 2023 |